Larkin JMG, et al. 5-year survival outcomes of the CheckMate 067 phase 3 trial of nivolumab plus ipilimumab (NIVO+IPI) combination therapy in advanced melanoma. Abstract LBA68_PR. ESMO Congress 2019, 28 sept, Barcelona, Spanje.
Eerste studie naar neoadjuvante immuuntherapie bij PCC van start
apr 2021 | Dermato-oncologie, Immuuntherapie